Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Depression Symptoms Improved in Just 48 Hours After a Single Psychedelic Dose (opens in a new tab)

scitechdaily.com · 2026-11-01

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of eight claims match the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

  • 3 supported
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredAfter six weeks, 53% of participants who received psilocybin were in remission, compared with 6% of those given a placebo.View evidenceHide evidence

As stated53% vs 6% remission at six weeks

Why this verdict

The profile supports a significant clinician-rated difference at about six weeks/day 42, but it does not provide remission rates or a 53% vs 6% remission comparison in the abstract-level evidence supplied. The exact remission claim cannot be verified at this evidence depth.

1

Study evidence

Clinician-rated MADRS: between-group differences favored psilocybin at day 15 and day 42 but not at day 365.Day 15 mean difference −11.03 (95% CI −16.65 to −5.42; P < .001); Day 42 mean difference −8.33 (95% CI −13.94 to −2.71; P = .004); Day 365 mean difference −3.68 (95% CI −9.30 to 1.94; P = .20).

“Secondary end points included MADRS scores on days 15, 42, and 365, as well as monthly self-reports (MADRS-S) of depressive symptoms, disability, quality of life, and anxiety throughout the 365-day follow-up.”
Claim 2 of 8Not coveredThe findings come from Sweden’s first randomized, double-blind trial of psilocybin for depression, conducted by researchers at Karolinska Institutet and published in JAMA Network Open.View evidenceHide evidence

Why this verdict

The profile verifies that the study was a double-blind, placebo-controlled randomized clinical trial in Stockholm/Sweden, but it does not verify the claims that it was Sweden’s first such trial, that it was conducted by Karolinska Institutet, or that it was published in JAMA Network Open. Those publication/institutional/priority details are not established by the supplied abstract-level profile.

1

Study evidence

Primary endpoint: greater reduction in clinician-rated MADRS at day 8 for psilocybin vs active placebo.-7.27 (95% CI -12.89 to -1.65); P = .01 (model-estimated between-group difference)

“This double-blind, placebo-controlled randomized clinical trial”
Claim 3 of 8Not coveredThe phase 2 trial enrolled 35 adults aged 20 to 65 with moderate to severe recurrent depression, and participants were randomly assigned to 25 mg psilocybin or niacin.View evidenceHide evidence

As stated35 adults; 25 mg psilocybin

Why this verdict

The profile supports enrollment of 35 adults with moderate-to-severe recurrent MDD and randomization to psilocybin 25 mg or niacin 100 mg. However, the supplied profile does not verify the phase 2 label or the exact age range of 20 to 65 years, so the full claim is not verifiable at this depth.

1

Study evidence

Primary endpoint: greater reduction in clinician-rated MADRS at day 8 for psilocybin vs active placebo.-7.27 (95% CI -12.89 to -1.65); P = .01 (model-estimated between-group difference)

“This double-blind, placebo-controlled randomized clinical trial”
Claim 4 of 8Not coveredEight days after treatment, depression scores fell by an average of 9.7 points in the psilocybin group versus 2.4 points in the placebo group, a 7.3-point difference that was statistically significant and considered clinically meaningful.View evidenceHide evidence

As stated9.7 vs 2.4 point drop; 7.3-point difference

Why this verdict

The profile supports a statistically significant day-8 between-group MADRS difference favoring psilocybin, with a model-estimated mean difference of about 7.27 points and P=.01. It does not provide the within-group average drops of 9.7 vs 2.4 points or verify the statement that the difference was considered clinically meaningful, so the full numerical claim is not verifiable from the abstract-level profile.

1

Study evidence

Primary endpoint: greater reduction in clinician-rated MADRS at day 8 for psilocybin vs active placebo.-7.27 (95% CI -12.89 to -1.65); P = .01 (model-estimated between-group difference)

“This double-blind, placebo-controlled randomized clinical trial”
Claim 5 of 8Not coveredPsilocybin was generally well tolerated, but two participants experienced severe, persistent anxiety that required medical attention, and most participants correctly guessed their treatment assignment.View evidenceHide evidence

As statedtwo participants

Why this verdict

The profile supports the safety portion: most treatment-emergent adverse events were transient and mild-to-moderate, no drug-related serious adverse events were reported, and two psilocybin recipients had persistent severe anxiety requiring medical attention. However, the supplied abstract-level profile does not report that most participants correctly guessed their treatment assignment, so the combined claim is not fully verifiable at this depth.

1

Study evidence

Most reported treatment-emergent adverse events were transient and of mild to moderate severity (abstract statement).

“Most reported treatment-emergent adverse events were transient and of mild to moderate severity.”
Claim 6 of 8SupportedA single dose of psilocybin produced rapid antidepressant effects in a small Swedish clinical trial, with improvements lasting for weeks.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a rapid antidepressant effect in this small randomized trial: the primary day-8 clinician-rated MADRS change favored psilocybin vs niacin, and secondary clinician-rated differences remained significant at days 15 and 42. Because this was an interventional randomized trial, the causal framing is acceptable, though the intervention was psilocybin with psychotherapeutic support rather than an unsupported drug-only dose.

1

Study evidence

Primary endpoint: greater reduction in clinician-rated MADRS at day 8 for psilocybin vs active placebo.-7.27 (95% CI -12.89 to -1.65); P = .01 (model-estimated between-group difference)

“This double-blind, placebo-controlled randomized clinical trial”
2

Study evidence

Clinician-rated MADRS: between-group differences favored psilocybin at day 15 and day 42 but not at day 365.Day 15 mean difference −11.03 (95% CI −16.65 to −5.42; P < .001); Day 42 mean difference −8.33 (95% CI −13.94 to −2.71; P = .004); Day 365 mean difference −3.68 (95% CI −9.30 to 1.94; P = .20).

“Secondary end points included MADRS scores on days 15, 42, and 365, as well as monthly self-reports (MADRS-S) of depressive symptoms, disability, quality of life, and anxiety throughout the 365-day follow-up.”
Claim 7 of 8SupportedSome participants reported improvements within two days, and antidepressant effects persisted for more than three months in self-reported assessments.View evidenceHide evidence

As statedwithin two days; more than three months

Why this verdict

The profile reports self-reported MADRS-S improvement beginning at day 2 and persisting through day 102, with isolated later effects. The story’s hedged framing that these were self-reported assessments and persisted for more than three months is consistent with the abstract-level evidence.

1

Study evidence

Clinician-rated MADRS: between-group differences favored psilocybin at day 15 and day 42 but not at day 365.Day 15 mean difference −11.03 (95% CI −16.65 to −5.42; P < .001); Day 42 mean difference −8.33 (95% CI −13.94 to −2.71; P = .004); Day 365 mean difference −3.68 (95% CI −9.30 to 1.94; P = .20).

“Secondary end points included MADRS scores on days 15, 42, and 365, as well as monthly self-reports (MADRS-S) of depressive symptoms, disability, quality of life, and anxiety throughout the 365-day follow-up.”
Claim 8 of 8SupportedThe difference was no longer statistically confirmed after one year, and the article says repeated treatments may be needed to prevent relapse.View evidenceHide evidence

As statedone year

Why this verdict

The profile reports that the clinician-rated day-365 difference was no longer statistically significant. It also states that durability beyond a single dose requires further study and supports further investigation of dosing strategies to extend durability, which is consistent with the story’s hedged statement that repeated treatments may be needed to prevent relapse.

1

Study evidence

Clinician-rated MADRS: between-group differences favored psilocybin at day 15 and day 42 but not at day 365.Day 15 mean difference −11.03 (95% CI −16.65 to −5.42; P < .001); Day 42 mean difference −8.33 (95% CI −13.94 to −2.71; P = .004); Day 365 mean difference −3.68 (95% CI −9.30 to 1.94; P = .20).

“Secondary end points included MADRS scores on days 15, 42, and 365, as well as monthly self-reports (MADRS-S) of depressive symptoms, disability, quality of life, and anxiety throughout the 365-day follow-up.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The intervention was not psilocybin alone: participants received a single 25 mg psilocybin dose or niacin 100 mg plus five psychotherapeutic support sessions over 17 days.

    The story claims focus on a single psilocybin dose versus niacin but do not reflect the accompanying psychotherapeutic support sessions, a material feature of the tested intervention.

    From Double-blind randomized clinical trial

  • Important limitations include the small sample size and single-site setting, limiting precision and generalizability.

    The story mentions the trial was small, but it does not reflect the single-site limitation or its implications for generalizability.

    From Double-blind randomized clinical trial; Randomized double-blind active-placebo-controlled trial (single-site); Double-bl

6 things the story did carry across
  • Randomized, double-blind, active-placebo-controlled trial design in 35 adults with moderate-to-severe recurrent MDD.
  • Primary endpoint was clinician-rated MADRS change from baseline to day 8, favoring psilocybin with a model-estimated between-group difference of about -7.27 points and P=.01.
  • Secondary clinician-rated outcomes favored psilocybin at days 15 and 42, but not at day 365.
  • Self-reported depressive symptoms improved beginning at day 2 and persisted through about day 102, with isolated later effects.
  • Safety profile: most adverse events were transient and mild-to-moderate, no drug-related serious adverse events were reported, and two psilocybin recipients had persistent severe anxiety requiring medical attention.
  • Durability beyond a single dose remains uncertain, and repeated or adjunctive strategies require further study.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether a single 25-mg dose of psilocybin (with psychotherapeutic support) produces a rapid antidepressant effect in moderate-to-severe recurrent major depressive disorder vs active placebo (niacin), with primary endpoint at day 8 on clinician-rated MADRS.Double-blind randomized clinical trialExpand

In plain English

Double-blind, placebo-controlled randomized clinical trial in 35 adults with moderate-to-severe recurrent MDD testing a single 25 mg dose of psilocybin plus brief psychotherapeutic support versus an active placebo (niacin 100 mg). The prespecified primary endpoint (between-group difference in change in clinician-rated MADRS from baseline to day 8) favored psilocybin (model-estimated mean difference -7.27; 95% CI -12.89 to -1.65; P = .01). Secondary analyses showed larger differences at days 15 and 42, no significant difference at day 365, early self-reported symptom improvement from day 2 with effects persisting through ~3 months on MADRS-S, and generally tolerable adverse events with two participants reporting persistent severe anxiety after psilocybin.

Key findings

  • Primary endpoint: greater reduction in clinician-rated MADRS at day 8 for psilocybin vs active placebo.-7.27 (95% CI -12.89 to -1.65); P = .01 (model-estimated between-group difference)
  • Clinician-rated secondary endpoints: significant between-group differences favoring psilocybin at days 15 and 42.Day 15: -11.03 (95% CI -16.65 to -5.42); P < .001. Day 42: -8.33 (95% CI -13.94 to -2.71); P = .004.
“This double-blind, placebo-controlled randomized clinical trial”
What this piece can’t prove
  • Single-site study (Northern Stockholm Psychiatric Clinic) which may limit generalizability.
  • Intervention was a single dose of psilocybin with brief psychotherapeutic support; durability beyond a single dose requires further study.

2 further details could not be confirmed from the summary.

2human in vivoAssess durability of antidepressant effects over longer follow-up (days 15, 42, 365 and monthly self-reports) and broader patient-reported outcomes (depressive symptoms, disability, quality of life, anxiety).Randomized double-blind active-placebo-controlled trial (single-site)Expand

In plain English

Within the same double-blind, randomized clinical trial cohort, secondary and longer-term efficacy outcomes showed that a single 25 mg psilocybin dose produced larger clinician-rated MADRS improvements than active placebo at days 15 and 42 but not at day 365; self-reported depressive symptoms (MADRS-S) showed an early reduction beginning day 2 that persisted through ~102 days with isolated later differences at days 283 and 343. Patient-reported outcomes (disability, quality of life, anxiety) were prespecified as monthly measures over 365 days but effect estimates for these outcomes are not reported in the abstract. Adverse events were mostly transient and mild-to-moderate; two psilocybin recipients reported persistent severe anxiety requiring medical attention.

Key findings

  • Clinician-rated MADRS: between-group differences favored psilocybin at day 15 and day 42 but not at day 365.Day 15 mean difference −11.03 (95% CI −16.65 to −5.42; P < .001); Day 42 mean difference −8.33 (95% CI −13.94 to −2.71; P = .004); Day 365 mean difference −3.68 (95% CI −9.30 to 1.94; P = .20).
  • Self-reported depressive symptoms (MADRS-S): psilocybin group had earlier and persisting reductions on self-report through ~102 days with isolated later differences.Day 2 mean difference −9.58 (95% CI −16.05 to −3.11; P = .004); Day 102 mean difference −6.60 (95% CI −13.01 to −0.19; P = .04).
“Secondary end points included MADRS scores on days 15, 42, and 365, as well as monthly self-reports (MADRS-S) of depressive symptoms, disability, quality of life, and anxiety throughout the 365-day follow-up.”
What this piece can’t prove
  • Small sample size reported in abstract (n = 35; 17 psilocybin, 18 niacin).
  • Results described here are from secondary and longer-term endpoints within the trial; abstract does not provide full statistical detail for all reported timepoints or outcomes.
  • Single-site trial; single-dose intervention (25 mg) limits inference about repeated dosing.

1 further detail could not be confirmed from the summary.

3human in vivoCharacterize safety/tolerability of psilocybin therapy vs active placebo, including treatment-emergent adverse events and serious adverse events over follow-up.Double-blind, placebo-controlled randomized clinical trialExpand

In plain English

Within this double-blind randomized trial of single-dose psilocybin (25 mg) versus active placebo (niacin, 100 mg) in 35 participants with recurrent MDD, most treatment-emergent adverse events were reported as transient and mild-to-moderate; no drug-related serious adverse events were reported; two participants in the psilocybin arm experienced persistent, severe anxiety requiring medical attention.

Key findings

  • Most reported treatment-emergent adverse events were transient and of mild to moderate severity (abstract statement).
  • No drug-related serious adverse events were reported (abstract statement).
“Most reported treatment-emergent adverse events were transient and of mild to moderate severity.”
What this piece can’t prove
  • Small sample size (35 participants; 17 psilocybin, 18 niacin) reduces precision for estimating adverse event rates and identifying rare harms.
  • The abstract does not detail management or outcomes of the two reported cases of persistent severe anxiety.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

And 28 more candidates considered.